Source: Accesswire

Press Release: Aqualung Therapeutics : First Patient Enrolled in the PUERTA Phase 2A ARDS Clinical Trial: Treatment with Aqualung Therapeutics ALT-100 mAb

Read full article »
Aqualung Therapeutics's Competitors | Aqualung Therapeutics's News | Aqualung Therapeutics's Financials
Stay up-to-date with the latest news on Aqualung Therapeutics
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Joe G.N. Garcia's photo - Founder & CEO of Aqualung Therapeutics

Founder & CEO

Joe G.N. Garcia

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Aqualung Therapeutics